Yosuke Nakaya

Yosuke Nakaya

Auto-generated profile, based on publicly available information

Yosuke Nakaya

Department of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 July 2022 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
YNYosuke Nakaya
Yosuke Nakaya
MIMika Imasaki
Mika Imasaki
MSMichinori Shirano
Michinori Shirano
KSKatsujun Shimizu
Katsujun Shimizu
NYNaoko Yagi
Naoko Yagi
TYTakahisa Yamane
Takahisa Yamane


1 June 2020 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Closed access
MTMinako Tsutsumi
Minako Tsutsumi
TYTakuro Yoshimura
Takuro Yoshimura
NTNaoko Tatsumi
Naoko Tatsumi
YNYosuke Nakaya
Yosuke Nakaya
HFHoyuri Fuseya
Hoyuri Fuseya
TYTakahisa Yamane
Takahisa Yamane

30 October 2023 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
YNYosuke Nakaya
Yosuke Nakaya
HKHideo Koh
Hideo Koh
TKTakaaki Konuma
Takaaki Konuma
YSYoshimitsu Shimomura
Yoshimitsu Shimomura
KIKen Ishiyama
Ken Ishiyama
HNHirohisa Nakamae
Hirohisa Nakamae
Allogeneic hematopoietic cell transplantation (allo-HCT) is the sole curative therapy for myelodysplastic syndrome (MDS). In the absence of an HLA-matched sibling donor, an HLA-matched unrelated donor (MUD) is considered the leading candidate. However, in recent decades, the alternative donor pool has been extended to HLA-haploidentical donors, especially with the development of graft-versus-host disease (GVHD) prophylaxis using post-transplantation cyclophosphamide (PTCy). Comparative data for haploidentical and MUD allo-HCT in patients with MDS are scarce. We retrospectively analyzed 697 adult patients with MDS who underwent HLA-haploidentical peripheral blood stem cell transplantation (haplo-PBSCT) with PTCy (n = 136), MUD bone marrow transplantation (MUD-BMT) (n = 465), or MUD peripheral blood stem cell transplantation (MUD-PBSCT) (n = 96) as their first allo-HCT between 2014 and 2020 using Japanese registry data. Multivariable analyses demonstrated faster neutrophil engraftment (hazard ratio [HR], 2.19; 95% confidence interval [CI], 1.65 to 2.90; P < .001) and platelet engraftment (HR, 2.31; 95% CI, 1.72 to 3.10; P < 0001) in the MUD-PBSCT cohort compared with the haplo-PBSCT cohort. MUD-BMT was associated with a higher incidence of grade II-IV acute GVHD than haplo-PBSCT (HR, 1.52; 95% CI, 1.00 to 2.29; P = .048). Among patients without in vivo T cell depletion using antithymocyte globulin (ATG) (haplo-PBSCT, n = 136; MUD-BMT, n = 446; MUD-PBSCT, n = 65), MUD-PBSCT recipients experienced faster hematopoietic recovery, MUD-BMT recipients (HR, 1.54; 95% CI, 1.02 to 2.32; P = .042) or MUD-PBSCT recipients (HR, 1.83; 95% CI, 1.06 to 3.18; P = .03) had a higher incidence of grade II-IV acute GVHD, and MUD-PBSCT recipients developed chronic GVHD more frequently than haplo-PBSCT recipients (HR, 1.74; 95% CI, 1.04 to 2.89; P = .034). There were no significant differences in overall survival, disease-free survival, GVHD-free relapse-free survival, relapse, or nonrelapse mortality in the haplo-PBSCT cohort versus the MUD-BMT or MUD-PBSCT cohorts. In conclusion, despite differences in the incidences of hematopoietic engraftment and GVHD depending on graft type and ATG use in MUD transplant recipients, major transplantation outcomes were comparable between recipients of haplo-PBSCT using PTCy and recipients of MUD-BMT or MUD-PBSCT.

24 May 2020 in Pathology International
Verified
Journal Article
Closed access
PDF file
YNYosuke Nakaya
Yosuke Nakaya
NINaomi Ishii
Naomi Ishii
YKYu Kasamatsu
Yu Kasamatsu
KSKatsujun Shimizu
Katsujun Shimizu
NTNaoko Tatsumi
Naoko Tatsumi
TYTakahisa Yamane
Takahisa Yamane

13 November 2022 in Journal of Infection and Chemotherapy
Verified
Journal Article
Closed access
YNYosuke Nakaya
Yosuke Nakaya
YNYasuhiro Nakashima
Yasuhiro Nakashima
NHNaonori Harada
Naonori Harada
KYKoichi Yamada
Koichi Yamada
YMYosuke Makuuchi
Yosuke Makuuchi
MHMasayuki Hino
Masayuki Hino